Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity
Galactosylation of immunoglobulin G (IgG) is reduced in rheumatoid arthritis (RA) and assumed to correlate with inflammation and altered humoral immunity. IgG hypogalactosylation also increases with age. To investigate dependencies in more detail, we compared IgG hypogalactosylation between patients with RA, patients with axial spondyloarthritis (axSpA), and healthy control subjects (HC), and we studied it in RA on the background of HLA-DRB1 shared epitope (SE), anticitrullinated protein antibodies (ACPA), and/or rheumatoid factor (RF) status.
Patients with RA (n = 178), patients with axSpA (n = 126), and HC (n = 119) were characterized clinically, and serum IgG galactosylation was determined by capillary electrophoresis. Markers of disease activity, genetic susceptibility, and serologic response included C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), DAS28, SE, HLA-B27, ACPA, and RF. Expression of glycosylation enzymes, including beta 1–4 galactosyltransferase (B4GALT3) activity, were estimated from transcriptome data for B-cell development (GSE19599) and differentiation to plasma cells (GSE12366).
IgG hypogalactosylation was restricted to RA and associated with increasing CRP levels (p < 0.0001). In axSpA, IgG hypogalactosylation was comparable to HC and only marginally increased upon elevated CRP. Restriction to RA was maintained after correction for CRP and age. Treatment with sulfasalazine resulted in significantly reduced IgG hypogalactosylation (p = 0.003) even after adjusting for age, sex, and CRP (p = 0.009). SE-negative/ACPA-negative RA exhibited significantly less IgG hypogalactosylation than all other strata (vs SE-negative/ACPA-positive, p = 0.009; vs SE-positive/ACPA-negative, p = 0.04; vs SE-positive/ACPA-positive, p < 0.02); however, this indicated a trend only after Bonferroni correction for multiple testing. In SE-positive/ACPA-negative RA IgG hypogalactosylation was comparable to ACPA-positive subsets. The relationship between IgG hypogalactosylation and disease activity was significantly different between strata defined by SE (CRP, p = 0.0003, pBonferroni = 0.0036) and RF (CRP, p < 0.0001, pBonferroni < 0.0012), whereas ACPA strata revealed only a nonsignificant trend (p = 0.15). Gene expression data indicated that the key enzyme for galactosylation of immunoglobulins, B4GALT3, is expressed at lower levels in B cells than in plasma cells.
Increased IgG hypogalactosylation in RA but not in axSpA points to humoral immune response as a precondition. Reduced B4GALT3 expression in B cells compared with plasma cells supports relatedness to early B-cell triggering. The differential influence of RA treatment on IgG hypogalactosylation renders it a potential diagnostic target for further studies.
KeywordsRheumatoid arthritis (RA) Axial spondyloarthritis (axSpA) HLA-DRB1 shared epitope (HLA-DRB1 SE) Anticitrullinated protein antibodies (ACPA) Rheumatoid factor (RF) IgG hypogalactosylation C-reactive protein (CRP) Disease Activity Score in 28 joints (DAS28)
Anticitrullinated protein antibody
Beta 1–4 galactosyltransferase 3
Disease Activity Score in 28 joints
Enzyme-linked immunosorbent assay
Erythrocyte sedimentation rate
Fragment crystallizable region
Agalactosylated immunoglobulin G
Monogalactosylated immunoglobulin G
Digalactosylated immunoglobulin G
Gene Expression Omnibus repository
Healthy control subject
Human leukocyte antigen
Nonradiographic axial spondyloarthritis
Several questions on IgG hypogalactosylation in RA are unaddressed. Comparing the time frame of changes in IgG galactosylation and C-reactive protein (CRP) in RA reveals a striking analogy in that IgG hypogalactosylation  and CRP elevations  precede RA onset by several years. Thus, the question arises whether IgG hypogalactosylation indicates specific processes involved in humoral autoimmunity or whether it simply reflects inflammatory activity. We addressed this question by analyzing IgG galactosylation in RA as well as in axial spondyloarthritis (axSpA). Spondyloarthritides represent chronic inflammatory diseases without relevant antibody reactivity and only moderate efficacy of B-cell depletion with rituximab [35, 36]. Because humoral autoimmunity in RA is influenced by HLA-DRB1 SE and is reflected by ACPA and/or RF synthesis, we tested whether these three factors are interrelated with IgG hypogalactosylation and whether the relationship between IgG hypogalactosylation and inflammatory activity differs in RA subsets defined by HLA-DRB1 SE, ACPA, or RF.
Patients and control subjects
Baseline characteristics of patients and healthy controls
RA (n = 178)
axSpA (n = 126)
HC (n = 119)
Age, years, mean ± SD
55.0 ± 12.4
44.3 ± 8.4
55.2 ± 13.5
Female sex, n (%)
Disease duration, years, median (IQR)
G0/G1 ratio, median (IQR)
CRP, mg/L, mean ± SD
19.4 ± 30.6a
5.8 ± 10.3
DAS28, mean ± SD
5.1 ± 1.4a
ACPA-positive, n (%)
RF-positive, n (%)
HLA-DRB1 SE-positive, n (%)
HLA-B27-positive, n (%)
Previous/ongoing RA therapy, n (%)
Laboratory diagnostics and HLA-DRB1 genotyping
ACPA were quantified at the time of enrollment with a second-generation enzyme-linked immunosorbent assay (ELISA) using the CCPlus Immunoscan kit (Euro-Diagnostica, Malmö, Sweden) for detection of RA . A cutoff value of 25 AU/ml was used. RF was quantified using an ELISA-based IgM-specific technique (cutoff value, 24 IU/ml) as previously described (DLD Diagnostika, Hamburg, Germany) . CRP and erythrocyte sedimentation rate (ESR) were characterized using standard techniques . SE was defined by HLA-DRB1 alleles with HLA-DRB1 chain residues 67Leu–69Glu–71Lys/Arg–74Ala–86Gly/Val and characterized using standard techniques (Dynal, Oslo, Norway; GenoVision, Vienna, Austria; PROTRANS, Ketsch, Germany) [39, 40].
Analysis of IgG-Fc N-glycans was performed as described previously  with minor modifications. Briefly, IgG was isolated from human serum using protein A Sepharose. IgG-Fc glycopeptides were separated from IgG antigen-binding fragment by pepsin digestion and isolated by ultrafiltration. After denaturation, IgG-Fc N-glycans were released by peptide:N-glycosidase F (Roche Applied Science, Indianapolis, IN, USA) digestion, separated with reversed-phase Supelco SP20SS resin microcolumns (Sigma-Aldrich, St. Louis, MO, USA) and subsequently desalted with graphite microcolumns (Agilent Technologies, Santa Clara, CA, USA). N-glycans were derivatized by methylation of carboxylic acid groups of terminal sialic acids to neutralize their negative charges, followed by purification to remove excess reagents. Subsequently, dried eluates were labeled with 8-aminopyrene-1,3,6-trisulfonic acid (APTS) (Sigma-Aldrich) at 55 °C for 2 h in darkness. Capillary electrophoresis of labeled N-glycans was performed on a Beckman P/ACE MDQ system equipped with laser-induced fluorescence detection (Beckman Coulter, Brea, CA, USA). Separation was achieved with reversed polarity on polyvinyl alcohol-coated capillaries (50 μm inner diameter, 50-cm effective separation length from injection to detector; Beckman Coulter) using the background electrolyte (Beckman Coulter). APTS-labeled maltose was used as an internal standard to normalize detected migration time. Migration time was expressed in glucose units using an APTS-labeled dextran hydrolysate ladder. Electropherogram quality was evaluated by intensities and signal-to-noise ratio of peaks detected in all samples. Data analysis was performed with 32 Karat 8.0 software (Beckman Coulter). Structural assignment of IgG-Fc glycans was performed as reported previously. In this study 22 peaks were detected, which represent 29 glycan structures. Relative intensities were calculated after normalization as the ratio of areas between individual peaks to all peaks. In peaks with relevant comigration, the N-glycan structure of the dominant peak defined the galactosylation type. Glycosylation traits were quantified by summing the corresponding peak areas, where the abbreviations depict the number of antennary N-acetylglucosamine (GlcNAc) (A), bisecting GlcNAc (B), core fucose (F), galactose (G1, G2), and sialic acids (S1, S2) (Fig. 1): agalactosylation (G0) = A2 + A2B + FA2 + FA2B; monogalactosylation (G1) = A2G1 + A2BG1 + FA2G1 + FA2G1 + FA2BG1 + FA2BG1 + A2G1S1 + FA2G1S1 + A2BG1S1 + FA2G1S1; and G0/G1 ratio = (G0)/(G1). Because G0 and G1 represent over 70% of total IgG-Fc glycosylation, the IgG G0/G1 ratio was used to characterize aberrant IgG galactosylation as described previously for analyses on whole serum N-glycans as well as purified IgG . Additionally, data on the main findings are presented for G0%, which represents the percentage of G0 among total IgG glycans.
Analysis of beta 1–4 galactosyltransferase activity in B cells and plasma cells
Beta 1–4 galactosyltransferase (B4GALT3) activity was estimated from transcriptome data for B-cell development (Gene Expression Omnibus accession number [GEO:GSE19599]) and differentiation to plasma cells (Gene Expression Omnibus accession number [GEO:GSE12366]) using data from the Gene Expression Omnibus (GEO) online repository [42, 43]. The respective data of this repository were derived from two independently pooled samples of each cell population that have subsequently been hybridized onto Applied Biosystems GeneChip Human Genome U133 Plus 2.0 microarrays (Thermo Fisher Scientific, Waltham, MA, USA). Array data have been uploaded into the BioRetis database (www.bioretis.de), and normalized signal intensities as well as group analyses have been tested.
Statistical analyses were performed using IBM SPSS Statistics 23.0 (IBM, Armonk, NY, USA) and Prism 6.0 software (GraphPad Software, La Jolla, CA, USA). The Kruskal-Wallis test followed by Dunn’s multiple comparisons test, the Wilcoxon rank-sum test, and the Mann-Whitney U test were used to analyze differences between groups. Associations between IgG G0/G1 ratio and disease-related parameters were evaluated by regression analysis. For secondary analyses (i.e., analyses of different IgG hypogalactosylation between RA subgroups defined by ACPA, RF, and SE as well as different relationships between IgG hypogalactosylation and activity markers in dependence of ACPA, RF, and SE), p values after Bonferroni correction for multiple testing assuming 12 secondary hypotheses are given.
IgG G0/G1 ratio in RA, axSpA, and HC
An age- and sex-corrected comparison of G0% between RA and axSpA or HC confirmed significantly higher IgG hypogalactosylation in RA than in axSpA or HC (p < 0.001 for both comparisons; G0% median [IQR], RA, 41.5 [38.2–47.2]; HC, 35.4 [29.6–40.4]; axSpA, 32.5 [28.6–38.0]).
In the RA cohort, we tested whether disease duration would influence the IgG G0/G1 ratio. When patients were categorized in quartiles of disease duration (median [minimum–maximum], first quartile, 6 months [1 week–17 months]; second quartile, 2.6 years [1.5–5.2 years]; third quartile, 7.6 years [5.3–10.6 years]; fourth quartile, 16.6 years [10.9–60.8 years]), nonparametric testing revealed no trend for higher IgG G0/G1 ratio with increasing disease duration (p = 0.64). However, when the different quartiles of disease duration were considered separately, the first quartile exhibited a relatively high IgG G0/G1 ratio, followed by a significant decline in the second quartile and a re-increase of IgG G0/G1 ratio in the third and fourth quartiles (IgG G0/G1 ratio, median [IQR], first quartile, 1.36 [1.17–1.82]; second quartile, 1.19 [1.08–1.35]; third quartile, 1.2 [1.07–1.54]; fourth quartile, 1.31 [1–17–1.73]).
When patients with RA were differentiated by previously untreated and treated patients, no difference with respect to IgG hypogalactosylation could be found between groups (p = 0.74). When we looked at specific drugs, those patients treated with sulfasalazine (n = 47) exhibited significantly less IgG hypogalactosylation than patients treated without sulfasalazine (n = 131) (IgG G0/G1, median [IQR], treated with sulfasalazine, 1.16 [1.07–1.29]; treated without sulfasalazine, 1.31 [1.1–1.66], p = 0.001; G0%, treated with sulfasalazine, 40.1 [37.3–42.5]; treated without sulfasalazine, 42.9 [38.6–49.5], p = 0.003). This finding remained statistically significant after correction for age, sex, and CRP level (p = 0.009 for IgG G0/G1 ratio as well as G0%). In contrast, methotrexate, leflunomide, hydroxychloroquine, and tumor necrosis factor inhibitors did not exhibit altered IgG galactosylation.
IgG G0/G1 ratio in RA and axSpA in relation to CRP level
IgG G0/G1 ratio in relation to ACPA, RF and HLA-DRB1 SE
Subsequently, we studied IgG G0/G1 ratio in RA subsets defined by combinations of SE and ACPA status (Fig. 6b). Interestingly, in SE-positive/ACPA-negative RA, the IgG G0/G1 ratio (1.25 [1.17–1.66]) was largely comparable to both ACPA-positive subsets (ACPA-positive/SE-negative, 1.32 [1.17–1.64]; ACPA-positive/SE-positive, 1.30 [1.07–1.77]). In SE-negative/ACPA-negative RA, the IgG G0/G1 ratio (1.13 [1.05–1.35]) was significantly lower than in all other RA subsets. RA subsets defined by SE and RF status exhibited quite comparable IgG G0/G1 ratios (Fig. 6c). If considering a multiple testing strategy, Bonferroni correction would indicate only a trend.
IgG G0/G1 ratio in axSpA subsets
Beta 1–4 galactosyltransferase 3 transcription in B cells and plasma cells
Analysis of glycosyltransferase transcription in B cells and plasma cells
Relationship between IgG G0/G1 ratio and disease activity in RA
IgG G0/G1 ratio was correlated with Disease Activity Score in 28 joints (DAS28), CRP, and ESR (p < 0.0001 for all tests). Analyses regarding ACPA, RF, and SE status confirmed these results in all RA subsets (data not shown).
In this study, IgG hypogalactosylation was found to be related to RA, whereas axSpA presented with levels comparable to HC (Fig. 2). Inflammatory activity as measured by CRP was related to increased IgG hypogalactosylation in RA but had only marginal effects in axSpA (Figs. 4 and 5). IgG hypogalactosylation was higher in RA than in axSpA and HC when age was considered as a confounding factor, with a tendency toward convergence after the sixth decade of life (Fig. 3). Overall, there was no trend for a continuous increase of IgG hypogalactosylation with increasing disease duration.
Hypogalactosylation of IgG in RA was first observed decades ago and is also found in other chronic inflammatory conditions . Whether this phenomenon is related solely to aberrant N-glycan formation during IgG synthesis  or to the use of alternative B-cell/plasma cell subsets , or whether altered N-glycan degradation makes some contribution, is unknown [47, 48, 49]. The increase of IgG agalactosylated glycoforms in RA has been discussed as being directly associated with reduced galactosyltransferase (GTase) activity in lymphocytes . Previous studies have shown a possible mechanism for posttranslational regulation of GTase activity in RA. Thus, in RA, either qualitative and quantitative changes of GTase expression could result in altered enzymatic activity or the activity of specific B-cell/plasma cell subsets with preference for agalactosylated IgG is increased in RA .
Our findings suggest that triggering of the humoral response is necessary for changes in IgG galactosylation, or at least that inflammation itself is not a sufficient precondition in this respect. This is further supported by transcriptomic data (Table 2) that show that B cells, before differentiating to plasma cells, express lower levels of enzymes involved in glycosylation of immunoglobulins, in particular B4GALT3, the key enzyme of IgG galactosylation. This supports the assumption of increased IgG hypogalactosylation in newly triggered humoral response. The phenomenon of IgG hypogalactosylation in our study could be overlaid by age, sex, and inflammation related effects in all three groups, RA, axSpA and HC.
The finding that patients treated with sulfasalazine showed significantly decreased IgG hypogalactosylation compared with those without sulfasalazine treatment seemed surprising because the specific mode of therapeutic action of this drug is mainly unknown. However, this result is of striking compatibility with an earlier report describing reduced lymphocytic GTase activity in patients with RA and a re-increase in those patients treated with sulfasalazine . On the basis of the information in this earlier report to IgG galactosylation, sulfasalazine treatment should reduce the amount of unoccupied potential galactosylation sites, thereby reducing IgG G0/G1 ratio and G0%, which is completely in agreement with our findings.
When looking for the influence of SE, ACPA, and RF on IgG hypogalactosylation (Fig. 6), SE-negative/ACPA-negative RA exhibited significantly less IgG hypogalactosylation than all other RA subsets, making this specific RA subset comparable to axSpA or HC from a glycophenotypic viewpoint. However, considering the Bonferroni correction for multiple testing qualifies these findings as trends, which should be addressed in further studies. On the other hand, IgG hypogalactosylation in SE-positive/ACPA-negative RA was at a level comparable to that in both ACPA-positive strata.
Correlation between IgG hypogalactosylation and inflammatory activity in RA has been described previously [27, 29, 51, 52]. Whether this relationship is due to an increased proinflammatory potential of hypogalactosylated IgG, or whether hypogalactosylation of IgG simply reflects an altered cellular activity or a shift in respective B-cell compartments (e.g., plasma cell, memory cell), is currently unknown. In our present study, the relationship between IgG hypogalactosylation and disease activity markers (Figs. 8 and 9) was dependent on SE, RF, and, with a statistically nonsignificant trend, on ACPA. The findings on the interrelationship of inflammatory activity and IgG hypogalactosylation could be interpreted as being that in seropositive RA, IgG hypogalactosylation is associated with lower CRP levels, or, in a more functional description, less inflammatory activity seems to be needed to induce aberrant IgG galactosylation. It could be considered that RF and ACPA may attenuate proinflammatory activity by capturing and eliminating the involved antigens as ICs, thereby interfering with a possible direct triggering of antigen-presenting cells and interleukin 6 as well as subsequent CRP production. Finally, association of IgG hypogalactosylation in HLA-DRB1 SE-positive patients with higher CRP levels suggests that antigen presentation in the context of SE is associated with a stronger proinflammatory immune activation prior to the involvement and differentiation of B cells, which seem to produce less IgG-galactosylating enzymes than plasma cells and thus would generate more hypogalactosylated IgG. These steps may depend on the extent of monocyte involvement, which contributes to the chronic inflammatory response by increased production, preterm release from bone marrow, reduced circulation time, and activation in the joint as reported recently . Furthermore, HLA-DRB4, which is preferentially connected to the HLA-DRB1 SE, may exhibit differential effects on immune activation . However, it should be mentioned that these interpretations are hypothetical and that the findings reported in Figs. 8 and 9 are based on analyses that could be affected by outliers and thus should be confirmed in independent studies.
The finding that in ACPA-positive RA the IgG G0/G1 ratio was significantly higher than in ACPA-negative RA (Fig. 6a), albeit losing statistical significance after correction for multiple testing, has been described previously when comparing purified anticitrullinated antibodies with repertoire IgG  and could be due to reduced galactosylation of ACPA. This finding would confirm the assumption that aberrant IgG galactosylation is related to altered humoral immunity . Interestingly, RF status did not influence IgG G0/G1 ratio (Fig. 6a). A possible explanation could be that in RF-positive individuals, the amount of activated cell types with a preference for agalactosylated IgG is lower than in ACPA-positive individuals.
Some limitations of our study have to be mentioned. Owing to multiple testing, some findings are at risk for false-positive reporting. Our primary hypothesis was the assumption that inflammation itself is not a sufficient precondition for IgG hypogalactosylation. We think that this hypothesis is supported by our data at a sufficiently low significance level without as well as with correction for potentially confounding factors. Other findings that are based on relatively small patient subgroups should be confirmed in independent validation cohorts in the future.
Our data support the assumption that inflammation itself is not a sufficient precondition for aberrant IgG galactosylation and that IgG hypogalactosylation in RA is reduced by specific treatments. Whether pretreatment IgG hypogalactosylation status would help in selection of specific treatment strategies or whether assessment of IgG hypogalactosylation during therapy could help with monitoring treatment responses would be an interesting topic for further studies.
The authors thank Peggy Thiele for excellent technical assistance and Silvia Pade for support in patient recruitment and clinical and laboratory data collection.
This work was supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung [BMBF]) through ArthroMark (grant number FKZ 01EC1009A).
Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.
CS, TH, and BH developed the hypotheses and conceived of and designed the study. CS, TH, UK, VB, GRB, DP, and BH coordinated sample acquisition and laboratory analyses. CS, TH, DP, and BH analyzed data. CS, TH, UK, GRB, DP, and BH interpreted the data. CS, TH, and BH drafted the manuscript. CS, TH, UK, GRB, DP, and BH critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the ethics committee of Charité – Universitätsmedizin Berlin. Participants were included in the study after they provided informed consent.
Consent for publication
All authors had full access to all data and approved the final version of the manuscript for publication.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 4.Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum. 2002;46(4):906–12.CrossRefPubMedGoogle Scholar
- 7.Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol. 2003;171(2):538–41.CrossRefPubMedGoogle Scholar
- 9.Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46.CrossRefPubMedGoogle Scholar
- 10.Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, Pedersen BV, Wohlfahrt J, Frisch M. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum. 2007;56(5):1446–53.CrossRefPubMedGoogle Scholar
- 15.Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol. 2000;37(12–13):697–706.CrossRefPubMedGoogle Scholar
- 19.Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–73.CrossRefPubMedGoogle Scholar
- 25.Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316(6027):452–7.CrossRefPubMedGoogle Scholar
- 27.Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, O’Donnell CI, Derber LA, Weinblatt ME, Shadick NA, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2239–48.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Ercan A, Cui J, Hazen MM, Batliwalla F, Royle L, Rudd PM, Coblyn JS, Shadick N, Weinblatt ME, Gregersen P, et al. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther. 2012;14(2):R43.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Bondt A, Rombouts Y, Selman MH, Hensbergen PJ, Reiding KR, Hazes JM, Dolhain RJ, Wuhrer M. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics. 2014;13(11):3029–39.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Van Beneden K, Coppieters K, Laroy W, De Keyser F, Hoffman IE, Van den Bosch F, Vander Cruyssen B, Drennan M, Jacques P, Rottiers P, et al. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis. 2009;68(8):1360–5.CrossRefPubMedGoogle Scholar
- 34.Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, de Gast T, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 2004;50(8):2423–7.CrossRefPubMedGoogle Scholar
- 35.Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62(5):1290–7.CrossRefPubMedGoogle Scholar
- 36.Wendling D, Dougados M, Berenbaum F, Brocq O, Schaeverbeke T, Mazieres B, Marcelli C, Leparc JM, Bertin P, Robin M, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol. 2012;39(12):2327–31.CrossRefPubMedGoogle Scholar
- 39.Hoppe B, Haupl T, Egerer K, Gruber R, Kiesewetter H, Salama A, Burmester GR, Dorner T. Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis. 2009;68(6):898–903.CrossRefPubMedGoogle Scholar
- 41.Schwedler C, Kaup M, Petzold D, Hoppe B, Braicu EI, Sehouli J, Ehlers M, Berger M, Tauber R, Blanchard V. Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulin G N-glycans of ovarian cancer patients. Electrophoresis. 2014;35(7):1025–31.CrossRefPubMedGoogle Scholar
- 42.Andersson A, Eden P, Olofsson T, Fioretos T. Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. BMC Med Genet. 2010;3:6.Google Scholar
- 53.Smiljanovic B, Radzikowska A, Kuca-Warnawin E, Kurowska W, Grun JR, Stuhlmuller B, Bonin M, Schulte-Wrede U, Sorensen T, Kyogoku C, et al. Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint. Ann Rheum Dis. 2018;77(2):300–8.CrossRefPubMedGoogle Scholar
- 54.Stuhlmuller B, Mans K, Tandon N, Bonin MO, Smiljanovic B, Sorensen TA, Schendel P, Martus P, Listing J, Detert J, et al. Genomic stratification by expression of HLA-DRB4 alleles identifies differential innate and adaptive immune transcriptional patterns - A strategy to detect predictors of methotrexate response in early rheumatoid arthritis. Clin Immunol. 2016;171:50–61.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.